NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Total Inventories

: $2.88 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

NovaBay Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $2.88 Mil. NovaBay Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $3.19 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. NovaBay Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.23.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. NovaBay Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 152.00.

Inventory Turnover measures how fast the company turns over its inventory within a year. NovaBay Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.60.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. NovaBay Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.85.

NovaBay Pharmaceuticals Total Inventories Historical Data

The historical data trend for NovaBay Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

0.49

0.61

3.22

3.44

2.88

NovaBay Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories																3.44	3.80	3.66	3.49	2.88

NovaBay Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

NovaBay Pharmaceuticals (AMEX:NBY) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

NovaBay Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.13	+	0.75 * 0.759	+	0.5 * 2.877	-	5.72
-	1.95	-	0)	/	11.2302
=	-0.23

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

NovaBay Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	3.185	/	1.912	*	365 / 4
	=	152.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

NovaBay Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	1.912	/	3.185
	=	0.60

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

NovaBay Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	3.185	/	3.727
	=	0.85

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

NovaBay Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

B9P:Germany

Address

2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608

Website

https://www.novabay.com

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Executives

Tommy Law	officer: Interim CFO	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin	officer: President, DERMAdoctor, LLC	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin	officer: Chief Product Officer	4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall	officer: General Counsel	5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng	director	NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov	director	2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones	officer: CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu	director	SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu	10 percent owner	LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu	officer: NEO - Sr Mgr and Controller	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit	director	95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng	director	1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang	director	2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh	officer: Interim CFO and Treasurer	2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd	10 percent owner	FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000